CSF3R and acute myeloid leukemia: Patients with CSF3R/CEBPA mutant AML have inferior outcomes to those with mutant CEBPA alone, arguing that the presence of Class I mutations in CSF3R may be an important determinant of chemotherapy resistance and relapse8.